Marco Weiergräber

Anna Papazoglou¹, 

Andreas Lundt¹, 

Carola Wormuth¹, 

Dan Ehninger², 

Christina Henseler¹, 

Julien Soós¹, 

Karl Broich¹, 

Marco Weiergräber¹ 

¹Department of Neuropsychopharmacology, Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM), 

²Molecular and Cellular Cognition Lab, German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE) 

Ralf Müller¹, 

Anna Papazoglou², 

Julien Soos², 

Andreas Lundt², 

Carola Wormuth², 

Christina Henseler², 

Dan Ehninger³, 

Karl Broich⁴, 

Marco Weiergräber² 

¹Department of Psychiatry and Psychotherapy, University of Cologne, 

²Department of Neuropsychopharmacology, Federal Institute for Drugs and Medical Devices, 

³Molecular and Cellular Cognition Lab, German Center for Neurodegenerative Diseases, 

⁴, Federal Institute for Drugs and Medical Devices 

Andreas Lundt^1,2, 

Julien Soos¹, 

Christina Henseler¹, 

Muhammad Imran Arshaad¹, 

Ralf Müller³, 

Dan Ehninger⁴, 

Jürgen Hescheler⁵, 

Agapios Sachinidis⁵, 

Karl Broich⁶, 

Carola Wormuth^1,7, 

Anna Papazoglou¹, 

Marco Weiergräber¹ 

¹Experimental Neuropsychopharmacology, Federal Institute for Drugs and Medical Devices, 

², KBRwyle GmbH, 

³Cognitive Neurophysiology, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Cologne, 

⁴Molecular and Cellular Cognition, German Center for Neurodegenerative Diseases (DZNE), 

⁵Institute of Neurophysiology, Faculty of Medicine, University of Cologne, 

⁶, Federal Institute for Drugs and Medical Devices (BfArM), 

⁷, Thescon GmbH